Skip to content

Microbiota and Metabolomics of Intestinal Type of Gastric Cancer

Microbiota and Metabolomics of Intestinal Type of Gastric Cancer in the Context of Atrophic Gastritis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06079554
Enrollment
32
Registered
2023-10-12
Start date
2024-03-31
Completion date
2025-08-30
Last updated
2024-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

Compare with the gastric cavity without cancerous transformation in atrophic gastritis, analyze the microbiota and metabolomics changes in intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.

Detailed description

This study adopts a prospective cohort study. The expected recruitment time for all participants is 6 months, and all cases are cases who would receive magnifying endoscopy examination. The extent of atrophy and the presence of early gastric cancer are determined under magnifying endoscopy. Cases are chose into the gastric cancer group and atrophic gastritis group in a 1:1 ratio. There are 16 cases of intestinal type of gastric cancer under the background of atrophic gastritis, and 16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy, totaling 32 cases. Analyze the characteristics of early gastric cancer under endoscopy, investigate the changes in microbiota and metabolomics of intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.

Interventions

None listed

Sponsors

Jilin University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* •Intestinal type of gastric cancer or atrophic gastritis * Underwent Endoscopic submucosal dissection(ESD)

Exclusion criteria

* • have simultaneously other cancer * have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases

Design outcomes

Primary

MeasureTime frameDescription
Metabolomics results of lesions and atrophic gastritis.1yearliquid chromatograph mass spectrometer metabolic profling

Secondary

MeasureTime frameDescription
microbiomics of lesions and atrophic gastritis.1 year16SrRNA analysis

Other

MeasureTime frameDescription
degree of gastric atrophy,1yearAccording to the classification of Kimura-Takemoto Classification (C1-O3)
endoscopic observation1yearNBI observation of atrophic background color, surrounding color of the lesion, lesion color, presence or absence of boundary transition zones, scattered intact glands within the lesion,presence of incomplete mesh patterns, and presence or absence of other early gastric cancer endoscopic manifestations.

Countries

China

Contacts

Primary ContactHong Xu, professor
18844097668@163.com18844097668
Backup ContactDong Yang, doctor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026